❤️‍🩹 Sensitized, Desensitized, Transplanted: CAR-T Opens a New Door in Kidney Transplantation

🧬 Groundbreaking NEJM report! Two highly sensitized kidney transplant candidates (cPRA ~99.995–99.998%) underwent successful transplantation after dual CD19- and BCMA-targeted CAR-T therapy. 🎯   Rather than simply removing antibodies, investigators targeted the cells that produce them—memory B cells and plasma cells. The result? Profound reduction in anti-HLA antibodies, successful transplantation, and no donor-specific antibody rebound during follow-up. 🚀   This study expands the horizon of CAR-T beyond oncology and may herald a new era in transplant immunology.   📖 NEJM 2026: Bhoj et al. #KidneyTransplant #CART #TransplantImmunology #PrecisionMedicine #MedicalInnovation #MedEd 🩺